Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, ...

People with the most common type of lung cancer whose disease has spread to the brain could be spared potentially harmful whole brain radiotherapy, according to new research published in The Lancet.

Brain metastases arising from gynecologic cancers, including ovarian, endometrial and cervical malignancies, present unique diagnostic and therapeutic challenges. Although these metastatic events are ...

TTFields treatment following stereotactic radiosurgery prolonged the time to intracranial progression for patients with brain metastases from NSCLC.

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced ...

“This case challenges current paradigms, demonstrating that amivantamab monotherapy can effectively target rare EGFR mutations, achieve durable extracranial and CNS disease control, and potentially ...

Stage 4 lung cancer, also called metastatic lung cancer, is the most aggressive and life-threatening stage of the disease. By this point, cancer has spread from the lungs to vital organs such as the ...

RAD101 targets fatty acid synthase, overexpressed in many solid tumors, to improve brain metastases imaging. Fast track designation by the FDA accelerates development for treatments addressing unmet ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...